Literature DB >> 20663946

Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation.

Martin Bommer1, Stephanie von Harsdorf, Hartmut Döhner, Donald Bunjes, Mark Ringhoffer.   

Abstract

We analyzed the frequency of neoplastic meningitis in patients with acute myeloid leukemia prior to allogeneic hematopoietic stem cell transplantation at our institution. Between 1996 and 2009, cerebrospinal fluid samples of 204 adult patients were examined during pre-transplant work-up for cell counts and, if abnormal, morphologically. We found blasts in cerebrospinal fluid samples of 17 patients with either persistent (n=9) or newly diagnosed (n=8) neoplastic meningitis. All patients proceeded to transplant. The proportion of patients with central nervous system involvement was significantly higher in patients with refractory disease at the time of transplantation compared with patients responding to prior systemic therapy (19% vs. 4.6%; P=0.003). Since most of the patients with central nervous system involvement were asymptomatic, cerebrospinal fluid evaluation should be considered at least in patients with refractory acute myeloid leukemia.

Entities:  

Mesh:

Year:  2010        PMID: 20663946      PMCID: PMC2966922          DOI: 10.3324/haematol.2010.025999

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  19 in total

1.  Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia.

Authors:  M M Bisschop; T Révész; M Bierings; J F van Weerden; E R van Wering; K Hählen; A van der Does-van den Berg
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

2.  Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

Authors:  J C Byrd; R B Weiss; D C Arthur; D Lawrence; M R Baer; F Davey; E S Trikha; A J Carroll; R Tantravahi; M Qumsiyeh; S R Patil; J O Moore; R J Mayer; C A Schiffer; C D Bloomfield
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

3.  Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.

Authors:  S-J Choi; J-H Lee; J-H Lee; S Kim; M Seol; Y-S Lee; J-S Lee; W-K Kim; H-S Chi; K-H Lee
Journal:  Leukemia       Date:  2004-11       Impact factor: 11.528

Review 4.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

5.  First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.

Authors:  Andreas K Buck; Martin Bommer; Malik E Juweid; Gerhard Glatting; Stephan Stilgenbauer; Felix M Mottaghy; Melanie Schulz; Thomas Kull; Donald Bunjes; Peter Möller; Hartmut Döhner; Sven N Reske
Journal:  J Nucl Med       Date:  2008-10-16       Impact factor: 10.057

6.  The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.

Authors:  Kevin E Sanders; Chul S Ha; Jorge E Cortes-Franco; Charles A Koller; Hagop M Kantarjian; James D Cox
Journal:  Cancer       Date:  2004-05-15       Impact factor: 6.860

7.  Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome.

Authors:  Hong Chang; Joseph Brandwein; Qi-Long Yi; Kathy Chun; Bruce Patterson; Bill Brien
Journal:  Leuk Res       Date:  2004-10       Impact factor: 3.156

8.  Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.

Authors:  Sandra Quijano; Antonio López; Juan Manuel Sancho; Carlos Panizo; Guillermo Debén; Cristina Castilla; José Antonio García-Vela; Antonio Salar; Natalia Alonso-Vence; Eva González-Barca; Francisco Javier Peñalver; Josefa Plaza-Villa; Marta Morado; José García-Marco; Jesús Arias; Javier Briones; Secundino Ferrer; Javier Capote; Concepción Nicolás; Alberto Orfao
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

9.  Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.

Authors:  J K Rees; R G Gray; D Swirsky; F G Hayhoe
Journal:  Lancet       Date:  1986-11-29       Impact factor: 79.321

10.  Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  T Ruutu; P Corradini; A Gratwohl; E Holler; J Apperley; G Dini; V Rocha; N Schmitz; G Socié; D Niederwieser
Journal:  Bone Marrow Transplant       Date:  2005-01       Impact factor: 5.483

View more
  6 in total

1.  Clinical outcome and efficacy of current anti-leukemic therapy for leptomeningeal involvement in acute myeloid leukemia.

Authors:  Ji Hyun Kwon; Young-Il Koh; Sung-Soo Yoon; Seonyang Park; Inho Kim
Journal:  Int J Hematol       Date:  2016-07-18       Impact factor: 2.490

2.  Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia.

Authors:  Shuntaro Ikegawa; Noriko Doki; Satoshi Kaito; Shuhei Kurosawa; Masahiro Sakaguchi; Kaito Harada; Keita Yamamoto; Yutaro Hino; Naoki Shingai; Yasushi Senoo; Daisuke Watanabe; Takeshi Hagino; Kosuke Yoshioka; Kyoko Watakabe; Aiko Igarashi; Yuho Najima; Takeshi Kobayashi; Kazuhiko Kakihana; Hisashi Sakamaki; Kazuteru Ohashi
Journal:  Pathol Oncol Res       Date:  2016-12-21       Impact factor: 3.201

3.  Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.

Authors:  Uri Rozovski; Maro Ohanian; Farhad Ravandi; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Jorge Cortes; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2014-11-03

4.  CNS Involvement in AML Patient Treated with 5-Azacytidine.

Authors:  Diamantina Vasilatou; Sotirios Papageorgiou; Efthymia Bazani; Athina Prasouli; Christina Economopoulou; Christoforos Roumpakis; Petros Karakitsos; George Dimitriadis; Vasiliki Pappa
Journal:  Case Rep Hematol       Date:  2014-08-14

5.  Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT.

Authors:  S Bohl; S von Harsdorf; M Mulaw; S Hofmann; A Babiak; C P Maier; J Schnell; L-M Hütter-Krönke; K Scholl; V Wais; R F Schlenk; L Bullinger; M Ringhoffer; H Döhner; D Bunjes; M Bommer; F Kuchenbauer
Journal:  Bone Marrow Transplant       Date:  2016-03-07       Impact factor: 5.483

6.  Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia.

Authors:  Nael Alakel; Friedrich Stölzel; Brigitte Mohr; Michael Kramer; Uta Oelschlägel; Christoph Röllig; Martin Bornhäuser; Gerhard Ehninger; Markus Schaich
Journal:  Cancer Manag Res       Date:  2017-03-29       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.